Edith T Zemanick1, Michael W Konstan2, Donald R VanDevanter3, Steven M Rowe4, J P Clancy5, Katherine Odem-Davis6, Michelle Skalland6, Nicole Mayer-Hamblett7. 1. Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address: edith.zemanick@childrenscolorado.org. 2. Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland OH USA; Rainbow Babies and Children's Hospital, Cleveland OH USA. 3. Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland OH USA. 4. Department of Medicine and the Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL USA. 5. Cystic Fibrosis Foundation, Bethesda, MD USA. 6. Seattle Children's Research Institute, Seattle, WA 98145, USA. 7. Seattle Children's Research Institute, Seattle, WA 98145, USA; Department of Biostatistics and Pediatrics, University of Washington, Seattle, WA 98195, USA.
Abstract
BACKGROUND: The Characterizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes (CHEC-SC) study is a large epidemiologic study designed to determine the relationship between sweat chloride response and clinical outcomes in people with cystic fibrosis (CF) on commercially approved CFTR modulators. A challenge to study feasibility was capturing sweat chloride measurements before modulator initiation. We tested the hypothesis that historic sweat chloride approximated contemporary pre-modulator values to estimate CFTR modulator-induced changes, allowing a single-visit study design. METHODS: GOAL and PROSPECT were multi-center prospective studies of individuals initiating ivacaftor or lumacaftor-ivacaftor. At enrollment, pre-modulator sweat chloride was measured and historic results recorded. Post-modulator sweat chloride was measured at 1, 3 and 6 months. For this analysis, differences between historic and pre-modulator sweat chloride were estimated. CFTR modulator-induced sweat chloride mean changes were compared using historic and pre-modulator sweat chloride. RESULTS: Paired historic and pre-modulator sweat chloride (n=406 participants) revealed a non-significant mean change of -1.0 mmol/L (95% CI: -2.71, 0.66) over an average of 17.2 years. Calculating sweat response to ivacaftor or lumacaftor-ivacaftor using historic or pre-modulator values resulted in similar estimates of modulator response. Based on these results, the CHEC-SC study was designed with a single, post-modulator sweat chloride measurement. CONCLUSIONS: Historic sweat chloride values provide a reliable estimate of pre-modulator sweat chloride for people starting on modulator therapy. The CHEC-SC study anticipates capturing approximately 5,000 sweat chloride values, providing an unprecedented understanding of sweat chloride across the CF population in the era of CFTR modulators.
BACKGROUND: The Characterizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes (CHEC-SC) study is a large epidemiologic study designed to determine the relationship between sweat chloride response and clinical outcomes in people with cystic fibrosis (CF) on commercially approved CFTR modulators. A challenge to study feasibility was capturing sweat chloride measurements before modulator initiation. We tested the hypothesis that historic sweat chloride approximated contemporary pre-modulator values to estimate CFTR modulator-induced changes, allowing a single-visit study design. METHODS: GOAL and PROSPECT were multi-center prospective studies of individuals initiating ivacaftor or lumacaftor-ivacaftor. At enrollment, pre-modulator sweat chloride was measured and historic results recorded. Post-modulator sweat chloride was measured at 1, 3 and 6 months. For this analysis, differences between historic and pre-modulator sweat chloride were estimated. CFTR modulator-induced sweat chloride mean changes were compared using historic and pre-modulator sweat chloride. RESULTS: Paired historic and pre-modulator sweat chloride (n=406 participants) revealed a non-significant mean change of -1.0 mmol/L (95% CI: -2.71, 0.66) over an average of 17.2 years. Calculating sweat response to ivacaftor or lumacaftor-ivacaftor using historic or pre-modulator values resulted in similar estimates of modulator response. Based on these results, the CHEC-SC study was designed with a single, post-modulator sweat chloride measurement. CONCLUSIONS: Historic sweat chloride values provide a reliable estimate of pre-modulator sweat chloride for people starting on modulator therapy. The CHEC-SC study anticipates capturing approximately 5,000 sweat chloride values, providing an unprecedented understanding of sweat chloride across the CF population in the era of CFTR modulators.
Authors: Steven M Rowe; Susanna A McColley; Ernst Rietschel; Xiaolei Li; Scott C Bell; Michael W Konstan; Gautham Marigowda; David Waltz; Michael P Boyle Journal: Ann Am Thorac Soc Date: 2017-02
Authors: Michael W Konstan; Edward F McKone; Richard B Moss; Gautham Marigowda; Simon Tian; David Waltz; Xiaohong Huang; Barry Lubarsky; Jaime Rubin; Stefanie J Millar; David J Pasta; Nicole Mayer-Hamblett; Christopher H Goss; Wayne Morgan; Gregory S Sawicki Journal: Lancet Respir Med Date: 2016-12-21 Impact factor: 30.700
Authors: Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn Journal: N Engl J Med Date: 2011-11-03 Impact factor: 91.245
Authors: Harry G M Heijerman; Edward F McKone; Damian G Downey; Eva Van Braeckel; Steven M Rowe; Elizabeth Tullis; Marcus A Mall; John J Welter; Bonnie W Ramsey; Charlotte M McKee; Gautham Marigowda; Samuel M Moskowitz; David Waltz; Patrick R Sosnay; Christopher Simard; Neil Ahluwalia; Fengjuan Xuan; Yaohua Zhang; Jennifer L Taylor-Cousar; Karen S McCoy Journal: Lancet Date: 2019-10-31 Impact factor: 79.321
Authors: B L Aalbers; R W Hofland; I Bronsveld; K M de Winter-de Groot; H G M Arets; A C de Kiviet; M M M van Oirschot-van de Ven; M A Kruijswijk; S Schotman; S Michel; C K van der Ent; H G M Heijerman Journal: J Cyst Fibros Date: 2020-05-21 Impact factor: 5.482
Authors: Frank J Accurso; Fredrick Van Goor; Jiuhong Zha; Anne J Stone; Qunming Dong; Claudia L Ordonez; Steven M Rowe; John Paul Clancy; Michael W Konstan; Heather E Hoch; Sonya L Heltshe; Bonnie W Ramsey; Preston W Campbell; Melissa A Ashlock Journal: J Cyst Fibros Date: 2014-03 Impact factor: 5.527
Authors: David P Nichols; Alex C Paynter; Sonya L Heltshe; Scott H Donaldson; Carla A Frederick; Steven D Freedman; Daniel Gelfond; Lucas R Hoffman; Andrea Kelly; Michael R Narkewicz; Jessica E Pittman; Felix Ratjen; Margaret Rosenfeld; Scott D Sagel; Sarah Jane Schwarzenberg; Pradeep K Singh; George M Solomon; Michael S Stalvey; John P Clancy; Shannon Kirby; Jill M Van Dalfsen; Margaret H Kloster; Steven M Rowe Journal: Am J Respir Crit Care Med Date: 2022-03-01 Impact factor: 30.528